Ning Li

In 2005, he graduated from Peking Union Medical University of China, majoring in eight-year direct clinical medicine; In 2011, he studied tumor immunity, targeting and gene therapy in Harvard University Medical School; Introduce the latest international tumor treatment methods and concepts into China, take the lead in the research of a variety of new drugs and treatment methods, and become the chief expert in the construction of the clinical research (GCP) platform of the Chinese Academy of Medical Sciences.